Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer

M. Lopez, M. Natali, L. Di Lauro, P. Vici, F. Pignatti, S. Carpano

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background. Male breast cancer (MBC) is considered an androgen-dependent tumor, and as in prostatic cancer, responses have been reported with use of antiandrogens or gonadotropin-releasing hormone analogs. Thus, it is reasonable to postulate that better results could be achieved by combining these two agents. Methods. Eleven men with recurrent or progressive carcinoma of the breast have been treated with buserelin 1500 μg subcutaneously daily in the first week and 600 μg daily subsequently and cyproterone acetate (CPA) 100 mg twice a day orally starting 24 hours before the first dose of buserelin. Results. Objective responses have been observed in seven patients with a median duration of 11.5 months (range, 9-24+ months). Responses were not correlated to the dominant site of disease. Three patients had stable disease lasting 5 months. Median survival was 18.5 months. Side effects primarily were decrease or loss of libido, impotence, and hot flushes. Conclusions. Total androgen blockade with buserelin and CPA seems effective in the treatment of patients with advanced cancer of the male breast, but its superiority over standard androgen suppression remains to be demonstrated.

Original languageEnglish
Pages (from-to)502-505
Number of pages4
JournalCancer
Volume72
Issue number2
Publication statusPublished - 1993

Fingerprint

Buserelin
Male Breast Neoplasms
Cyproterone Acetate
Androgens
Androgen Antagonists
Libido
Erectile Dysfunction
Gonadotropin-Releasing Hormone
Prostatic Neoplasms
Therapeutics
Breast Neoplasms
Survival
Neoplasms

Keywords

  • buserelin
  • cyproterone acetate
  • hormonal treatment
  • male breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lopez, M., Natali, M., Di Lauro, L., Vici, P., Pignatti, F., & Carpano, S. (1993). Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer, 72(2), 502-505.

Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. / Lopez, M.; Natali, M.; Di Lauro, L.; Vici, P.; Pignatti, F.; Carpano, S.

In: Cancer, Vol. 72, No. 2, 1993, p. 502-505.

Research output: Contribution to journalArticle

Lopez, M, Natali, M, Di Lauro, L, Vici, P, Pignatti, F & Carpano, S 1993, 'Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer', Cancer, vol. 72, no. 2, pp. 502-505.
Lopez M, Natali M, Di Lauro L, Vici P, Pignatti F, Carpano S. Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer. 1993;72(2):502-505.
Lopez, M. ; Natali, M. ; Di Lauro, L. ; Vici, P. ; Pignatti, F. ; Carpano, S. / Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. In: Cancer. 1993 ; Vol. 72, No. 2. pp. 502-505.
@article{9889d0100f0e4111a38402db958c6609,
title = "Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer",
abstract = "Background. Male breast cancer (MBC) is considered an androgen-dependent tumor, and as in prostatic cancer, responses have been reported with use of antiandrogens or gonadotropin-releasing hormone analogs. Thus, it is reasonable to postulate that better results could be achieved by combining these two agents. Methods. Eleven men with recurrent or progressive carcinoma of the breast have been treated with buserelin 1500 μg subcutaneously daily in the first week and 600 μg daily subsequently and cyproterone acetate (CPA) 100 mg twice a day orally starting 24 hours before the first dose of buserelin. Results. Objective responses have been observed in seven patients with a median duration of 11.5 months (range, 9-24+ months). Responses were not correlated to the dominant site of disease. Three patients had stable disease lasting 5 months. Median survival was 18.5 months. Side effects primarily were decrease or loss of libido, impotence, and hot flushes. Conclusions. Total androgen blockade with buserelin and CPA seems effective in the treatment of patients with advanced cancer of the male breast, but its superiority over standard androgen suppression remains to be demonstrated.",
keywords = "buserelin, cyproterone acetate, hormonal treatment, male breast cancer",
author = "M. Lopez and M. Natali and {Di Lauro}, L. and P. Vici and F. Pignatti and S. Carpano",
year = "1993",
language = "English",
volume = "72",
pages = "502--505",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer

AU - Lopez, M.

AU - Natali, M.

AU - Di Lauro, L.

AU - Vici, P.

AU - Pignatti, F.

AU - Carpano, S.

PY - 1993

Y1 - 1993

N2 - Background. Male breast cancer (MBC) is considered an androgen-dependent tumor, and as in prostatic cancer, responses have been reported with use of antiandrogens or gonadotropin-releasing hormone analogs. Thus, it is reasonable to postulate that better results could be achieved by combining these two agents. Methods. Eleven men with recurrent or progressive carcinoma of the breast have been treated with buserelin 1500 μg subcutaneously daily in the first week and 600 μg daily subsequently and cyproterone acetate (CPA) 100 mg twice a day orally starting 24 hours before the first dose of buserelin. Results. Objective responses have been observed in seven patients with a median duration of 11.5 months (range, 9-24+ months). Responses were not correlated to the dominant site of disease. Three patients had stable disease lasting 5 months. Median survival was 18.5 months. Side effects primarily were decrease or loss of libido, impotence, and hot flushes. Conclusions. Total androgen blockade with buserelin and CPA seems effective in the treatment of patients with advanced cancer of the male breast, but its superiority over standard androgen suppression remains to be demonstrated.

AB - Background. Male breast cancer (MBC) is considered an androgen-dependent tumor, and as in prostatic cancer, responses have been reported with use of antiandrogens or gonadotropin-releasing hormone analogs. Thus, it is reasonable to postulate that better results could be achieved by combining these two agents. Methods. Eleven men with recurrent or progressive carcinoma of the breast have been treated with buserelin 1500 μg subcutaneously daily in the first week and 600 μg daily subsequently and cyproterone acetate (CPA) 100 mg twice a day orally starting 24 hours before the first dose of buserelin. Results. Objective responses have been observed in seven patients with a median duration of 11.5 months (range, 9-24+ months). Responses were not correlated to the dominant site of disease. Three patients had stable disease lasting 5 months. Median survival was 18.5 months. Side effects primarily were decrease or loss of libido, impotence, and hot flushes. Conclusions. Total androgen blockade with buserelin and CPA seems effective in the treatment of patients with advanced cancer of the male breast, but its superiority over standard androgen suppression remains to be demonstrated.

KW - buserelin

KW - cyproterone acetate

KW - hormonal treatment

KW - male breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0027191851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027191851&partnerID=8YFLogxK

M3 - Article

C2 - 8319180

AN - SCOPUS:0027191851

VL - 72

SP - 502

EP - 505

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -